Potential Infectious Complications in Pig Xenograft Donors and Recipients
Preclinical and clinical xenotransplantation trials have shown that successful outcomes depend on a number of factors including the prevention of xenozoonoses. Preclinical trials involving pig kidneys and hearts transplanted into various non-human primates have revealed the potential impact of pig p...
Saved in:
| Main Authors: | , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Frontiers Media S.A.
2025-01-01
|
| Series: | Transplant International |
| Subjects: | |
| Online Access: | https://www.frontierspartnerships.org/articles/10.3389/ti.2024.13594/full |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1841528028122841088 |
|---|---|
| author | Nicolas J. Mueller Linda Scobie |
| author_facet | Nicolas J. Mueller Linda Scobie |
| author_sort | Nicolas J. Mueller |
| collection | DOAJ |
| description | Preclinical and clinical xenotransplantation trials have shown that successful outcomes depend on a number of factors including the prevention of xenozoonoses. Preclinical trials involving pig kidneys and hearts transplanted into various non-human primates have revealed the potential impact of pig pathogens being present in the transplanted organ/tissue, mainly viruses. The concept of “designated pathogen-free donor animals” was developed to ensure elimination of pathogens during the breeding of donor animals to mitigate this occurrence. This is a challenging process as confirmation of presence and absence of some pathogen, in particular for latent viruses, requires a validated armamentarium of direct and indirect tests. The importance of using the correct diagnostic regimen was highlighted during the first pig-to-man cardiac transplantation with both porcine cytomegalovirus (PCMV), also known as porcine roseolovirus (PRV), and porcine circovirus (PCV) detected in the transplanted organ and in the patient. To further improve xenotransplantation and to achieve trials in Europe it is important that we use these data to inform process for diagnostics both in donor and recipients before and after xenotransplantation to ensure safety. As part of this sensitive and specific pathogen detection systems should be validated and readily available. |
| format | Article |
| id | doaj-art-cc4b6e6217054aa1b18383b4d6e299f5 |
| institution | Kabale University |
| issn | 1432-2277 |
| language | English |
| publishDate | 2025-01-01 |
| publisher | Frontiers Media S.A. |
| record_format | Article |
| series | Transplant International |
| spelling | doaj-art-cc4b6e6217054aa1b18383b4d6e299f52025-01-15T04:11:13ZengFrontiers Media S.A.Transplant International1432-22772025-01-013710.3389/ti.2024.1359413594Potential Infectious Complications in Pig Xenograft Donors and RecipientsNicolas J. Mueller0Linda Scobie1Division of Infectious Diseases and Hospital Epidemiology, University Zurich, University Hospital Zurich, Zurich, SwitzerlandDepartment of Biological and Biomedical Sciences, School of Health and Life Sciences, Glasgow Caledonian University, Glasgow, Scotland, United KingdomPreclinical and clinical xenotransplantation trials have shown that successful outcomes depend on a number of factors including the prevention of xenozoonoses. Preclinical trials involving pig kidneys and hearts transplanted into various non-human primates have revealed the potential impact of pig pathogens being present in the transplanted organ/tissue, mainly viruses. The concept of “designated pathogen-free donor animals” was developed to ensure elimination of pathogens during the breeding of donor animals to mitigate this occurrence. This is a challenging process as confirmation of presence and absence of some pathogen, in particular for latent viruses, requires a validated armamentarium of direct and indirect tests. The importance of using the correct diagnostic regimen was highlighted during the first pig-to-man cardiac transplantation with both porcine cytomegalovirus (PCMV), also known as porcine roseolovirus (PRV), and porcine circovirus (PCV) detected in the transplanted organ and in the patient. To further improve xenotransplantation and to achieve trials in Europe it is important that we use these data to inform process for diagnostics both in donor and recipients before and after xenotransplantation to ensure safety. As part of this sensitive and specific pathogen detection systems should be validated and readily available.https://www.frontierspartnerships.org/articles/10.3389/ti.2024.13594/fullxenotransplantationpreclinical trialsclinical trialsporcine virusesnon-human primates |
| spellingShingle | Nicolas J. Mueller Linda Scobie Potential Infectious Complications in Pig Xenograft Donors and Recipients Transplant International xenotransplantation preclinical trials clinical trials porcine viruses non-human primates |
| title | Potential Infectious Complications in Pig Xenograft Donors and Recipients |
| title_full | Potential Infectious Complications in Pig Xenograft Donors and Recipients |
| title_fullStr | Potential Infectious Complications in Pig Xenograft Donors and Recipients |
| title_full_unstemmed | Potential Infectious Complications in Pig Xenograft Donors and Recipients |
| title_short | Potential Infectious Complications in Pig Xenograft Donors and Recipients |
| title_sort | potential infectious complications in pig xenograft donors and recipients |
| topic | xenotransplantation preclinical trials clinical trials porcine viruses non-human primates |
| url | https://www.frontierspartnerships.org/articles/10.3389/ti.2024.13594/full |
| work_keys_str_mv | AT nicolasjmueller potentialinfectiouscomplicationsinpigxenograftdonorsandrecipients AT lindascobie potentialinfectiouscomplicationsinpigxenograftdonorsandrecipients |